文献速递肝病

原发性硬化性胆管炎组织学评分系统预后价值的验证:一项国际队列研究

Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study.
PubMed 文献 · Hepatology · 2017-01-11

本研究在欧洲七家机构收集119例原发性硬化性胆管炎(PSC)患者肝活检,用Nakanuma、Ishak和Ludwig评分系统评估,由6位肝病理学家独立评分。中位随访142个月,三种分期系统均为终点2和3的独立预测因子,仅Nakanuma与终点1独立相关;观察者间一致性中等至显著。

要点

  • Nakanuma、Ishak和Ludwig分期系统均为PSC肝移植和肝相关事件的独立预测因子
  • 仅Nakanuma分期系统与PSC相关死亡和肝移植复合终点独立相关
  • Nakanuma分期观察者间一致性中等(κ=0.56),其余评分系统一致性显著

核心结论

  • 研究证实Nakanuma、Ishak和Ludwig分期系统对PSC疾病进展具有独立预后价值,并首次证明其可重复性。
  • Nakanuma分期系统整合慢性胆道疾病特征,再次显示最强的预测价值。

研究设计与样本

  • 多中心队列研究,从欧洲七家机构收集PSC患者肝活检。
  • 共纳入119例PSC患者,中位随访142个月。
  • 采用Nakanuma、Ishak和Ludwig评分系统进行组织学评分,由6位肝病理学家独立评分评估观察者间一致性。
  • 采用单变量和多变量Cox比例风险模型评估临床、生化及三种组织学评分系统对复合终点的预测价值。

主要发现

  • 随访期间31例患者死亡(其中20例为PSC相关死亡),31例接受肝移植,35例发生一次或以上肝相关事件。
  • Nakanuma系统:终点2的HR为3.16(95%CI 1.49-6.68),终点3的HR为2.05(95%CI 1.17-3.57)。
  • Ishak系统:终点2的HR为1.55(95%CI 1.10-2.18),终点3的HR为1.43(95%CI 1.10-1.85)。
  • Ludwig系统:终点2的HR为2.62(95%CI 1.19-5.80),终点3的HR为2.06(95%CI 1.09-3.89)。
  • 仅Nakanuma分期系统与终点1独立相关:HR为2.14(95%CI 1.22-3.77)。

关键数值与推荐

  • 终点1为PSC相关死亡和肝移植,终点2为肝移植,终点3为肝相关事件。
  • 三种分期系统均为终点2和终点3的独立预测因子。
  • 仅Nakanuma分期系统与终点1独立相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Histologic scoring systems specific for primary sclerosing cholangitis (PSC) are not validated. We recently determined the applicability and prognostic value of three histological scoring systems in a single PSC cohort. The aim of this study was to validate their prognostic use and reproducibility across a multicenter PSC cohort. Liver biopsies from PSC patients were collected from seven European institutions. Histologic scoring was performed using the Nakanuma, Ishak, and Ludwig scoring systems. Biopsies were independently scored by six liver pathologists for interobserver agreement. The prognostic value of clinical, biochemical, and all three histologic scoring systems on predicting composite endpoints 1 (PSC-related death and liver transplantation), 2 (liver transplantation), and 3 (liver-related events), was assessed using univariable and multivariable Cox proportional hazards modeling. A total of 119 PSC patients were identified, and the median follow-up was 142 months. During follow-up, 31 patients died (20 PSC-related deaths), 31 patients underwent liver transplantation, and 35 patients experienced one or more liver-related events. All three staging systems were independent predictors of endpoints 2 and 3 (Nakanuma system: hazard ratio [HR], 3.16 [95% confidence interval (CI), 1.49-6.68] for endpoint 2 and HR, 2.05 [95% CI, 1.17-3.57] for endpoint 3; Ishak system: HR, 1.55 [95% CI, 1.10-2.18] for endpoint 2 and HR, 1.43 [95% CI, 1.10-1.85] for endpoint 3; Ludwig system: HR, 2.62 [95% CI, 1.19-5.80] for endpoint 2 and HR, 2.06 [95% CI, 1.09-3.89] for endpoint 3). Only the Nakanuma staging system was independently associated with endpoint 1: HR, 2.14 (95% CI, 1.22-3.77). Interobserver agreement was moderate for Nakanuma stage (κ = 0.56) and substantial for Nakanuma component fibrosis (κ = 0.67), Ishak stage (κ = 0.64), and Ludwig stage (κ = 0.62). CONCLUSION: We confirm the independent prognostic value and demonstrate for the first time the reproducibility of staging disease progression in PSC using the Nakanuma, Ishak, and Ludwig staging systems. The Nakanuma staging system-incorporating features of chronic biliary disease-again showed the strongest predictive value. (Hepatology 2017;65:907-919).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. de Vries EM, de Krijger M, Färkkilä M, et al. Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study. Hepatology. 2017. PMID: 27880989. doi:10.1002/hep.28963

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。